Clonal mast cell disorders, Hymenoptera venom allergy and venom immunotherapy
Authors:
D. Kapustová 1; L. Kapustová 1; O. Petrovičová 1; E. Jurková-Malicherová 1; A. Bobčáková 2; B. Šlenker 1; A. Markocsy 1; I. Kecskés 3; M. Jeseňák 1,2,4
Published in:
Transfuze Hematol. dnes,31, 2025, No. 1, p. 27-35.
Category:
Original Papers
doi:
https://doi.org/10.48095/cctahd2025prolekare.cz1
Overview
Introduction: Clonal mast cell disease and/or increased basal serum tryptase concentration are among the risk factors for a more severe life-threatening anaphylactic reaction following a Hymenoptera insect sting. Because of the risk carried by these patients, the single available causal therapy – venom immunotherapy (VIT) should be recommended for each such patient. Material and methods: We designed a prospective study consisting of 93 patients (58 men, 35 women) who met the indication criteria for VIT treatment. Patients were enrolled and data was collected from 2015 to 2023. We defined the basic characteristics of the group, we focused on the identification of patients with an elevated concentration of serum basal tryptase (> 8 ng/mL) and systemic mastocytosis, the details of their systemic allergic reaction after a Hymenoptera insect sting, treatment tolerance, and occurrence of adverse effects. Results: From a total of 93 enrolled patients treated with VIT, we recorded persistently elevated concentrations of serum basal tryptase (sBT) > 8 ng/mL in 15 patients (16.7%). We diagnosed systemic mastocytosis in one patient. In patients with elevated sBT values, we observed loss of consciousness and hypotension more frequently during a systemic allergic reaction after a Hymenoptera sting. From the point of view of treatment tolerance, we observed a roughly comparable incidence of adverse effects and the predominant majority of adverse effects were in terms of local reactions. A total of 53.3% of patients treated with VIT with elevated concentration of sBT overcame natural re-exposure to Hymenoptera insects, while not a single patient developed a systemic allergic reaction requiring the administration of an adrenaline autoinjector. Conclusion: Hymenoptera venom allergy is a life-threatening condition, and its occurrence is much more frequent, and its course more severe in patients with elevated basal serum tryptase concentrations and/or clonal mast cell disease. In each patient with a confirmed clonal mast cell disorder, it is necessary to search for the occurrence of an allergic reaction to Hymenoptera insect venom in the patient’s history and to consider venom immunotherapy as the only causal treatment.
Keywords:
systemic mastocytosis – clonal mast cell proliferation disorders – Hymenoptera venom – venom immunotherapy – hereditary alpha-tryptasemia – serum basal tryptase
Sources
1. Kačar M, Rijavec M, Šelb J, Korošec P. Clonal mast cell disorders and hereditary a-tryptasemia as risk factors for anaphylaxis. Clin Exp Allergy. 2023; 53 (4): 392–404.
2. Bonadonna P, Scaffidi L. Hymenoptera anaphylaxis as a clonal mast cell disorder. Immunol Allergy Clin North Am. 2018; 38 (3): 455–468.
3. O‘Connell MP, Lyons JJ. Hymenoptera venom-induced anaphylaxis and hereditary alpha-tryptasemia. Curr Opin Allergy Clin Immunol. 2020; 20 (5): 431–437.
4. Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy. 2018; 73 (4): 744–764.
5. Adib-Tezer H, Bayerl C. Honeybee and wasp venom allergy: sensitization and immunotherapy. J Dtsch Dermatol Ges. 2018; 16 (10): 1228–1247.
6. Hochmuth L, Hadvabová S, Hrubiško M, et al. Štandardné postupy diagnostiky, liečby a prevencie alergie na jed blanokrídleho hmyzu. Ministerstvo zdravotníctva Slovenskej republiky 2021; č. ŠP 0200. https: //www.standardnepostupy.sk/standardy-klinicka-imunologia-a-alergologia/
7. Biló MB, Pravettoni V, Bignardi D, et al. Hymenoptera venom allergy: management of children and adults in clinical practice. Brief. J Investig Allergol Clin Immunol. 2018; 29 (3): 180–205.
8. Zanotti R, Tanasi I, Bernardelli A, Orsolini G, Banadonna P. Bone marrow mastocytosis: a diagnostic challenge. J Clin Med. 2021; 10 (7): 1420.
9. Alvarez-Twose I, Zanotti R, González-de-Olano D, et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insectinduced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol. 2014; 133 (2): 520–528.
10. Alvarez-Twose I, Matito A. Mastocytosis presenting as insect anaphylaxis. Cur Opin Allergy Clin Immunol. 2019; 19 (5): 468–474.
11. Zanotti R, Lombardo C, Passalacqua G, et al. Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol. 2015; 136 (1): 135–139.
12. Alfaya Arias T, Soriano Gómis V, Soto Mera T, et al. Key issues in Hymenoptera venom allergy: an update. J Investig Allergol Clin Immunol. 2017; 27 (1): 19–31.
13. Valent P, Bonadonna P, Hartman K, et al. Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome. Int Arch Allergy Immunol. 2019; 180 (1): 44–51.
14. Stoevesandt J, Trautmann A. Risk factors in bee and Vespula venom allergy: state of the art. Allerg J Int. 2022; 31 (1): 1–10.
15. Lyons JJ, Greiner G, Hoermann G, Metcalfe DD. Incorporating tryptase genotyping into the workup and diagnosis of mast cell diseases and reactions. J Allergy Clin Immunol Pract. 2022; 10 (8): 1964–1973.
16. Luskin KT, White AA, Lyons JJ. The genetic basis and clinical impact of hereditary alpha-tryptasemia. J Allergy Clin Immunol Pract. 2021; 9 (6): 2235–2242.
17. Lyons JJ, Chovanec J, O’Conell MP, et al. Heritable risk for severe anaphylaxis associated with increased a-tryptase – encoding germline copy number at TPSAB1. J Allergy Clin Immunol. 2021; 147 (2): 622–632.
18. Wu R, Lyons, JJ. Hereditary alpha-tryptasemia: a commonly inherited modifier of anaphylaxis. Cur Allerg Asthma Rep. 2021; 21 (5): 33.
19. Rybníček O, Seberová E. Průvodce alergenovou imunoterapií. Doporučení České alergologie a klinické imunologie ČLS JEP. TIGIS spol. s. r. o. Praha: 2021: 58–64. ISBN 978-80-87323-18-2.
20. Selcuk A, Baysan A. Venom immunotherapy in indolent systemic mastocytosis with high serum tryptase level. Hum Vaccin Immunother. 2021; 17 (6): 1599–1603.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2025 Issue 1
- Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
- The Importance of Hydration in Wound Healing
- Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
- Prognostic Significance of Subclinical Joint Changes on MRI in Hemophilia
Most read in this issue
- Vitamin D and its importance in lymphomas
- Levels and signifi cance of vitamin D in patients with malignant lymphomas
- Aktualita z kongresu ASH 2024 Molekulární genetika určuje směr léčby AML
- Cardiovascular complications that may be caused by anti-myeloma drugs